Evolving Biology,
Advancing Tomorrow
Engineering nature's catalyst for a
new era of therapeutics
For billions of years, nature has evolved enzymes and biological systems with extraordinary precision. Today, advances in biotechnology allow us to go beyond studying these systems and engineer them. By harnessing enzymes, nature’s most versatile catalysts, we can design smarter, more selective ways to manufacture therapeutics and transform
how they are made.
When biology becomes the blueprint, the possibilities are endless.
Scaling the future of RNA therapies
Oligonucleotide therapeutics are redefining what is possible in medicine, moving from niche applications into high-prevalence indications with the potential to reshape standard of care across major increasing challenges. As this modality advances toward broader commercialization, developers face intensifying pressure to reconcile complex chemistries with scalable, efficient, and CMC‑robust manufacturing.
By developing integrated engineered-enzyme solutions for manufacturing complex oligonucleotides such as siRNAs, ASOs, and their bioconjugates, we unlock a fundamentally new path to high-purity, industrial-scale production—enabling next-generation RNA and DNA therapies to reach far more patients than traditional methods can support.
Scaling the future of RNA therapies
Oligonucleotide therapeutics are redefining what is possible in medicine, evolving from applications constrained by manufacturing scale into high-prevalence indications with the potential to reshape standards of care across complex diseases.
As this modality advances toward broader commercialization, developers face intensifying pressure to reconcile complex chemistries with scalable, efficient, and CMC‑robust manufacturing.
By developing integrated engineered-enzyme solutions for manufacturing complex oligonucleotides such as siRNAs, ASOs, and their bioconjugates, we unlock a fundamentally new path to high-purity, industrial-scale production—enabling next-generation RNA and DNA therapies to reach far more patients than traditional methods can support.
Powered by ZymeLeap™
A platform built to engineer and deliver superior enzymes that make next‑generation oligonucleotide therapeutics truly manufacturable at scale.
Microfluidics
Microfluidic droplets miniaturise reactions and let us test up to 10 million variants per day, expanding sequence space far beyond plate‑based methods while cutting reagent use and waste.
Bioinformatics
Computational tools that rapidly explore and map vast sequence space to pinpoint the most promising enzyme variants for each application.
Advanced Enzyme Engineering
Diverse libraries designed, screened, and validated under real process conditions to deliver high‑performance biocatalysts ready for commercial manufacturing
With Integrated
Operational Support
ZymeLeap™ is complemented by deep process development and manufacturing expertise, translating hits into process-ready enzymes from microreactor screening to 150 L scale-up.
Powering your Progress
From first concepts to process-ready enzymes, we work alongside you to turn complex biology into scalable solutions
.webp)
Our Growing Enzyme Portfolio
Available up to API commercial production.
Enzyme Engineering Services
Hear It From Our Customers
“We are deeply impressed with our partnership with Allozymes. Allozymes team designed, synthesized, and screened millions of enzyme variants in less than 6 months to identify the best performing enzymes. They produce our desired results and exceed expectations with their speed-scaling testing technology. They put project success as the major priority. A first foundational step of a highly collaborative long-term partnership.”
.webp)
“Bonumose's project with Allozymes has resulted in achievement of its success milestones. During that process, Bonumose was impressed with Alllozyme's collaborative and dynamic approach to achieving our goals.”
%20(2).webp){kind=logo}
“Partnering with Allozymes has been a highly rewarding collaborative experience. Their deep expertise in synthetic biology and commitment to sustainable innovation have helped us to innovate and develop next-generation technologies in the manufacture of specialty chemicals used in the lubricant and construction markets. The partnership has been marked by open dialogue, scientific rigor, and a shared vision for a more sustainable future. We see this as the beginning of a long-term, impactful partnership.”
Meet us at upcoming events
Where we'll be next
